Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia

Molecular Therapy

Volumn 21, Issue 4, 2013, Pages 877-886

  Schmiedel, Benjamin Joachim ^a   Werner, Antje ^a   Steinbacher, Julia ^a   Nuebling, Tina ^a   Buechele, Corina ^a   Grosse Hovest, Ludger ^a   Salih, Helmut Rainer ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN; LIGAND; RITUXIMAB; TUMOR NECROSIS FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; DEGRANULATION; DRUG EXPOSURE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LEUKEMIA; LEUKEMIA CELL; NATURAL KILLER CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; UPREGULATION;

EID: 84878562713     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.11     Document Type: Article

References (50)

1. Vivier, E, Raulet, DH, Moretta, A, Caligiuri, MA, Zitvogel, L, Lanier, LL et al. (2011). Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
2. Lanier, LL (2005). NK cell recognition. Annu Rev Immunol 23: 225-274.
3. Ruggeri, L, Capanni, M, Casucci, M, Volpi, I, Tosti, A, Perruccio, K et al. (1999). Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339.
4. Ruggeri, L, Capanni, M, Urbani, E, Perruccio, K, Shlomchik, WD, Tosti, A et al. (2002). Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
5. Elkins, WL, Pickard, A and Pierson, GR (1984). Defcient expression of class-I HLA in some cases of acute leukemia. Cancer Immunol Immunother 18: 91-100.
6. Demanet, C, Mulder, A, Deneys, V, Worsham, MJ, Maes, P, Claas, FH et al. (2004). Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecifcities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 103: 3122-3130.
7. Lowdell, MW, Craston, R, Samuel, D, Wood, ME, O'Neill, E, Saha, V et al. (2002). Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 117: 821-827.
8. Pierson, BA and Miller, JS (1996). CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 88: 2279-2287.
9. Tajima, F, Kawatani, T, Endo, A and Kawasaki, H (1996). Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 10: 478-482.
10. Moretta, L and Moretta, A (2004). Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 23: 255-259.
11. Shevach, EM and Stephens, GL (2006). The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol 6: 613-618.
12. Nocentini, G and Riccardi, C (2009). GITR: a modulator of immune response and infammation. Adv Exp Med Biol 647: 156-173.
13. Placke, T, Kopp, HG and Salih, HR (2010). Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation. Clin Dev Immunol 2010: 239083.
14. Ko, K, Yamazaki, S, Nakamura, K, Nishioka, T, Hirota, K, Yamaguchi, T et al. (2005). Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med 202: 885-891.
15. Cohen, AD, Diab, A, Perales, MA, Wolchok, JD, Rizzuto, G, Merghoub, T et al. (2006). Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 66: 4904-4912.
16. Ramirez-Montagut, T, Chow, A, Hirschhorn-Cymerman, D, Terwey, TH, Kochman, AA, Lu, S et al. (2006). Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 176: 6434-6442.
17. Cho, JS, Hsu, JV and Morrison, SL (2009). Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity. Cancer Immunol Immunother 58: 1057-1069.
18. Piao, J, Kamimura, Y, Iwai, H, Cao, Y, Kikuchi, K, Hashiguchi, M et al. (2009). Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours. Immunology 127: 489-499.
19. Imai, N, Ikeda, H, Tawara, I, Wang, L, Wang, L, Nishikawa, H et al. (2009). Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specifc CD8+ T cells with tumor regression. Cancer Sci 100: 1317-1325.
20. Levings, MK, Sangregorio, R, Sartirana, C, Moschin, AL, Battaglia, M, Orban, PC et al. (2002). Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 196: 1335-1346.
21. Tuyaerts, S, Van Meirvenne, S, Bonehill, A, Heirman, C, Corthals, J, Waldmann, H et al. (2007). Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol 82: 93-105.
22. Baltz, KM, Krusch, M, Bringmann, A, Brossart, P, Mayer, F, Kloss, M et al. (2007). Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 21: 2442-2454.
23. Liu, B, Li, Z, Mahesh, SP, Pantanelli, S, Hwang, FS, Siu, WO et al. (2008). GITR negatively regulates activation of primary human NK cells by blocking proliferative signals and increasing NK cell apoptosis. J Biol Chem 283: 8202-8210.
24. Baessler, T, Krusch, M, Schmiedel, BJ, Kloss, M, Baltz, KM, Wacker, A et al. (2009). Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res 69: 1037-1045.
25. Buechele, C, Baessler, T, Wirths, S, Schmohl, JU, Schmiedel, BJ and Salih, HR (2012). Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia 26: 991-1000.
26. Weiner, GJ (2010). Rituximab: mechanism of action. Semin Hematol 47: 115-123.
27. Adams, GP and Weiner, LM (2005). Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157.
28. Platsoucas, CD, Fernandes, G, Gupta, SL, Kempin, S, Clarkson, B, Good, RA et al. (1980). Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: augmentation by in vitro treatment with interferon. J Immunol 125: 1216-1223.
29. Ziegler, HW, Kay, NE and Zarling, JM (1981). Defciency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer 27: 321-327.
30. Kay, NE and Zarling, JM (1984). Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a defciency of azurophilic cytoplasmic granules in putative NK cells. Blood 63: 305-309.
31. Jaglowski, SM, Alinari, L, Lapalombella, R, Muthusamy, N and Byrd, JC (2010). The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116: 3705-3714.
32. Ofazoglu, E and Audoly, LP (2010). Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2: 14-19.
33. Beck, A, Wurch, T, Bailly, C and Corvaia, N (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10: 345-352.
34. Horton, HM, Bernett, MJ, Pong, E, Peipp, M, Karki, S, Chu, SY et al. (2008). Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 68: 8049-8057.
35. Foyil, KV and Bartlett, NL (2010). Anti-CD30 Antibodies for Hodgkin lymphoma. Curr Hematol Malig Rep 5: 140-147.
36. Horton, HM, Bernett, MJ, Peipp, M, Pong, E, Karki, S, Chu, SY et al. (2010). Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116: 3004-3012.
37. Robak, T (2009). GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 10: 588-596.
38. Lazar, GA, Dang, W, Karki, S, Vafa, O, Peng, JS, Hyun, L et al. (2006). Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103: 4005-4010.
39. Armour, KL, Clark, MR, Hadley, AG and Williamson, LM (1999). Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities. Eur J Immunol 29: 2613-2624.
40. Bowles, JA and Weiner, GJ (2005). CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 304: 88-99.
41. Dunn, GP, Koebel, CM and Schreiber, RD (2006). Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6: 836-848.
42. Baltz, KM, Krusch, M, Baessler, T, Schmiedel, BJ, Bringmann, A, Brossart, P et al. (2008). Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. Blood 112: 3735-3743.
43. Ma, Y, Lin, BR, Lin, B, Hou, S, Qian, WZ, Li, J et al. (2009). Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin 30: 364-371.
44. Locksley, RM, Killeen, N and Lenardo, MJ (2001). The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
45. Buechele, C, Baessler, T, Schmiedel, BJ, Schumacher, CE, Grosse-Hovest, L, Rittig, K et al. (2012). 4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. Eur J Immunol 42: 737-748.
46. Parkhurst, MR, Riley, JP, Dudley, ME and Rosenberg, SA (2011). Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 17: 6287-6297.
47. Koene, HR, Kleijer, M, Algra, J, Roos, D, von dem Borne, AE and de Haas, M (1997). Fc gammaRIIIa-158V/F polymorphism infuences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90: 1109-1114.
48. McLaughlin, P, Grillo-López, AJ, Link, BK, Levy, R, Czuczman, MS, Williams, ME et al. (1998). Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833.
49. Schmiedel, BJ, Arélin, V, Gruenebach, F, Krusch, M, Schmidt, SM and Salih, HR (2011). Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer 128: 2911-2922.
50. Hofmann, M, Große-Hovest, L, Nübling, T, Pyz, E, Bamberg, ML, Aulwurm, S et al. (2012). Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia 26: 1228-1237.